Promising Growth and Strategic Financial Moves Make Sol-Gel Technologies a Strong BuyValuation and Risks. We value Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of ~$180M in total for the company's commercial and late-stage portfolio. We forecast a $156M valuation for SGT-610, based on a 40% probability of approval. The total firm value is $200M, or a price objective of $50 per share, assuming roughly 4.1M fully-diluted shares outstanding as of end-2026. We remind investors that we do not include any contribution from either SGT-310 or any Sol-Gel-formulated generic topical products in our valuation assessment.